A Broad Application of CRISPR Cas9 in Infectious, Inflammatory and Neurodegenerative Diseases

Area of Science:

• Neuroimmunology
• Neuropharmacology
• Molecular Biology

Background:

• Microglia are the primary immune cells in the central nervous system (CNS).
• Microglial activation is a common feature in neurodegenerative diseases like Alzheimer's disease (AD), Parkinson's disease (PD), and HIV-associated neurocognitive disorders (HAND).
• Current treatments for neurodegenerative diseases are limited, and existing neuroimmune modulators lack cell specificity.

Purpose of the Study:

• To explore the potential of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 technology for targeted microglial signaling.
• To highlight recent advancements in CRISPR/Cas9 applications for neurodegenerative disorders.
• To discuss these advancements within the context of neuroimmune pharmacology.

Main Methods:

• Review of recent scientific literature on CRISPR/Cas9 applications in neurodegenerative disease research.
• Analysis of CRISPR/Cas9's mechanism as a genome editing tool.
• Focus on neuroimmune pharmacology and cell-specific targeting strategies.

Main Results:

• CRISPR/Cas9 technology has emerged as a powerful tool for precise genome editing.
• This technology holds promise for selectively targeting microglial cell signaling pathways.
• Potential for developing novel therapeutic strategies for neurodegenerative disorders with improved specificity.

Conclusions:

• Targeting microglial signaling with CRISPR/Cas9 offers a promising avenue for treating neurodegenerative diseases.
• The specificity of CRISPR/Cas9 can overcome the limitations of current non-specific neuroimmune modulators.
• Further research into CRISPR/Cas9 applications is crucial for advancing neuroimmune pharmacology and CNS disease treatment.